Eversept Partners LP Sells 132,661 Shares of Alector, Inc. (NASDAQ:ALEC)

Eversept Partners LP reduced its position in Alector, Inc. (NASDAQ:ALEC) by 39.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 200,095 shares of the company’s stock after selling 132,661 shares during the period. Eversept Partners LP’s holdings in Alector were worth $378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC grew its holdings in Alector by 26.1% during the 4th quarter. Hsbc Holdings PLC now owns 57,983 shares of the company’s stock valued at $109,000 after buying an additional 12,004 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Alector by 71.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock valued at $28,000 after purchasing an additional 6,096 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Alector by 21.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 882,120 shares of the company’s stock worth $1,667,000 after acquiring an additional 157,231 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Alector by 78.3% during the fourth quarter. XTX Topco Ltd now owns 50,971 shares of the company’s stock valued at $96,000 after buying an additional 22,381 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Alector by 63.0% during the 4th quarter. Renaissance Technologies LLC now owns 915,738 shares of the company’s stock valued at $1,731,000 after acquiring an additional 353,988 shares during the period. 85.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALEC. Morgan Stanley reaffirmed an “underweight” rating and set a $1.50 target price (down from $3.00) on shares of Alector in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Alector in a research note on Thursday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Alector presently has an average rating of “Hold” and an average target price of $3.50.

Alector Stock Up 5.8 %

NASDAQ:ALEC opened at $0.97 on Tuesday. Alector, Inc. has a 52 week low of $0.87 and a 52 week high of $6.78. The stock’s fifty day moving average is $1.34 and its two-hundred day moving average is $2.44. The stock has a market capitalization of $96.45 million, a price-to-earnings ratio of -0.57 and a beta of 0.73.

Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The firm had revenue of $54.24 million for the quarter, compared to analyst estimates of $20.41 million. On average, sell-side analysts expect that Alector, Inc. will post -1.88 EPS for the current fiscal year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.